New Users of Metformin Are at Low Risk of Incident Cancer

Libby, Gillian; Donnelly, Louise A.; Donnan, Peter T.; Alessi, Dario R.; Morris, Andrew D.; Evans, Josie M. M.
September 2009
Diabetes Care;Sep2009, Vol. 32 Issue 9, p1620
Academic Journal
OBJECTIVE -- The antidiabetic properties of metformin are mediated through its ability to activate the AMP-activated protein kinase (AMPK). Activation of AMPK can suppress tumor formation and inhibit cell growth in addition to lowering blood glucose levels. We tested the hypothesis that metformin reduces the risk of cancer in people with type 2 diabetes. RESEARCH DESIGN AND METHODS-- In an observational cohort study using record-linkage databases and based in Tayside, Scotland, U.K., we identified people with type 2 diabetes who were new users of metformin in 1994-2003. We also identified a set of diabetic comparators, individually matched to the metformin users by year of diabetes diagnosis, who had never used metformin. In a survival analysis we calculated hazard ratios for diagnosis of cancer, adjusted for baseline characteristics of the two groups using Cox regression. RESULTS -- Cancer was diagnosed among 7.3% of 4,085 metformin users compared with 11.6% of 4,085 comparators, with median times to cancer of 3.5 and 2.6 years, respectively (P < 0.001). The unadjusted hazard ratio (95% CI) for cancer was 0.46 (0.40-0.53). After adjusting for sex, age, BMI, A1C, deprivation, smoking, and other drug use, there was still a significantly reduced risk of cancer associated with metformin: 0.63 (0.53-0.75). CONCLUSIONS-- These results suggest that metformin use may be associated with a reduced risk of cancer. A randomized trial is needed to assess whether metformin is protective in a population at high risk for cancer.


Related Articles

  • Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer. Bodmer, Michael; Meier, Christian; Krähenbühl, Stephan; Jick, Susan S.; Meier, Christoph R. // Diabetes Care;Jun2010, Vol. 33 Issue 6, p1304 

    OBJECTIVE -- To evaluate whether use of oral hypoglycemic agents is associated with an altered breast cancer risk in women. RESEARCH DESIGN AND METHODS-- Using the U.K.-based General Practice Research Database, we conducted a nested case-control analysis among 22,621 female users of oral...

  • Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk. Miele, Luca; Bosetti, Cristina; Turati, Federica; Rapaccini, Gianlodovico; Gasbarrini, Antonio; La Vecchia, Carlo; Boccia, Stefania; Grieco, Antonio // Gastroenterology Research & Practice;5/13/2015, Vol. 2015, p1 

    Introduction. Metabolic conditions, including type 2 diabetes, have been related to hepatocellular carcinoma (HCC) risk. We have further analyzed the role of diabetes and antidiabetic treatments on HCC. Methods. Data derived from a hospital-based case-control study (Italy, 2005–2012) on...

  • Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes. Hagberg, K W; McGlynn, K A; Sahasrabuddhe, V V; Jick, S // British Journal of Cancer;10/28/2014, Vol. 111 Issue 9, p1710 

    Background:Type II diabetes increases liver cancer risk but the risk may be mitigated by anti-diabetic medications. However, choice of medications is correlated with diabetes duration and severity, leading to confounding by indication.Methods:To address this association, we conducted a nested...

  • Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer. MORDEN, NANCY E.; LIU, STEPHEN K.; SMITH, JEREMY; MACKENZIE, TODD A.; SKINNER, JONATHAN; KORC, MURRAY // Diabetes Care;Sep2011, Vol. 34 Issue 9, p1965 

    OBJECTIVE--In vitro evidence suggests insulin glargine promotes tumors; observational human studies are conflicting. We aimed to expand understanding of this potential treatment risk. RESEARCH DESIGN AND METHODS--This retrospective cohort study of type 2 diabetic patients >68 years old used...

  • DIABETES AND CANCER. Raz, Itamar // Problemy Endokrinologii;2017 Supplement, p6 

    To date, the medical literature has indicated that diabetic patients experience an increase in the incidence of cancer. The main organs that are involved are liver, pancreas, lungs, ovaries and breast. The risk for early mortality also seems to be increased when compared to non-diabetic...

  • Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone. LEWIS, JAMES D.; FERRARA, ASSIAMIRA; PENG, TIFFANY; HEDDERSON, MONIQUE; BILKER, WARREN B.; QUESENBERRY JR., CHARLES P.; VAUGHN, DAVID J.; NESSEL, LISA; SELBY, JOSEPH; STROM, BRIAN L. // Diabetes Care;Apr2011, Vol. 34 Issue 4, p916 

    OBJECTIVE--Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy. This is an interim report of an ongoing cohort study examining the association between pioglitazone therapy and the risk of bladder cancer in patients...

  • Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes. FERRARA, ASSIAMIRA; LEWIS, JAMES D.; QUESENBERRY JR., CHARLES P.; PENG, TIFFANY; STROM, BRIAN L.; VAN DEN EEDEN, STEPHEN K.; EHRLICH, SAMANTHA F.; HABEL, LAUREL M. // Diabetes Care;Apr2011, Vol. 34 Issue 4, p923 

    OBJECTIVE--To explore whether treatment with pioglitazone was associated with risk of incident cancer at the 10 most common sites (prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma [NHL], pancreas, kidney/renal pelvis, rectal, and melanoma). RESEARCH DESIGN AND...

  • Metformin and Diabetic Kidney Disease: A Mini-Review on Recent Findings. Nasri, Hamid; Rafieian-Kopaei, Mahmoud // Iranian Journal of Pediatrics;Oct2014, Vol. 24 Issue 5, p565 

    Metformin, an oral anti-diabetic agent in the biguanide class is a widely prescribed drug to treat high blood glucose in patients with type 2 diabetes mellitus. Metformin has three different roles, including blood glucose regulatory effect, protection of kidney tubular cell by acting as an...

  • Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 study.  // Current Medical Literature: Diabetes;2011, Vol. 28 Issue 4, p143 

    The article discusses an analysis of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 study on the prognostic implications of glucose-lowering treatment in diabetic patients with acute myocardial infarction and the possible benefits of metformin therapy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics